Cargando…
Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
INTRODUCTION: To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurv...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168549/ https://www.ncbi.nlm.nih.gov/pubmed/35759237 http://dx.doi.org/10.1002/iid3.640 |
_version_ | 1784721034744692736 |
---|---|
author | Sendi, Parham Thierstein, Marc Widmer, Nadja Babongo Bosombo, Flora Büchi, Annina Elisabeth Güntensperger, Dominik Blum, Manuel Raphael Baldan, Rossella Tinguely, Caroline Gahl, Brigitta Heg, Dik Theel, Elitza S. Berbari, Elie Endimiani, Andrea Gowland, Peter Niederhauser, Christoph |
author_facet | Sendi, Parham Thierstein, Marc Widmer, Nadja Babongo Bosombo, Flora Büchi, Annina Elisabeth Güntensperger, Dominik Blum, Manuel Raphael Baldan, Rossella Tinguely, Caroline Gahl, Brigitta Heg, Dik Theel, Elitza S. Berbari, Elie Endimiani, Andrea Gowland, Peter Niederhauser, Christoph |
author_sort | Sendi, Parham |
collection | PubMed |
description | INTRODUCTION: To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign. METHODS: The cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires. RESULTS: The mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose. CONCLUSION: These data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals. |
format | Online Article Text |
id | pubmed-9168549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91685492022-06-07 Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort Sendi, Parham Thierstein, Marc Widmer, Nadja Babongo Bosombo, Flora Büchi, Annina Elisabeth Güntensperger, Dominik Blum, Manuel Raphael Baldan, Rossella Tinguely, Caroline Gahl, Brigitta Heg, Dik Theel, Elitza S. Berbari, Elie Endimiani, Andrea Gowland, Peter Niederhauser, Christoph Immun Inflamm Dis Original Articles INTRODUCTION: To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign. METHODS: The cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires. RESULTS: The mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose. CONCLUSION: These data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals. John Wiley and Sons Inc. 2022-06-06 /pmc/articles/PMC9168549/ /pubmed/35759237 http://dx.doi.org/10.1002/iid3.640 Text en © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Sendi, Parham Thierstein, Marc Widmer, Nadja Babongo Bosombo, Flora Büchi, Annina Elisabeth Güntensperger, Dominik Blum, Manuel Raphael Baldan, Rossella Tinguely, Caroline Gahl, Brigitta Heg, Dik Theel, Elitza S. Berbari, Elie Endimiani, Andrea Gowland, Peter Niederhauser, Christoph Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
title | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
title_full | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
title_fullStr | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
title_full_unstemmed | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
title_short | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
title_sort | serosurveillance after a covid‐19 vaccine campaign in a swiss police cohort |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168549/ https://www.ncbi.nlm.nih.gov/pubmed/35759237 http://dx.doi.org/10.1002/iid3.640 |
work_keys_str_mv | AT sendiparham serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT thiersteinmarc serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT widmernadja serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT babongobosomboflora serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT buchianninaelisabeth serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT guntenspergerdominik serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT blummanuelraphael serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT baldanrossella serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT tinguelycaroline serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT gahlbrigitta serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT hegdik serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT theelelitzas serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT berbarielie serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT endimianiandrea serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT gowlandpeter serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT niederhauserchristoph serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort |